Cantor Fitzgerald Estimates Invivyd FY2025 Earnings

Key Points

• Cantor Fitzgerald projects Invivyd's FY2025 earnings at ($0.55) per share, with a target stock price of $10.00 and an "Overweight" rating.
• The company reported a loss of ($0.12) earnings per share for the last quarter, falling short of the consensus estimate of ($0.04).
• Insider selling has occurred, with insider Jill Andersen reducing her stake by 36.91% after selling over 49,000 shares at an average price of $0.57.

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Invivyd in a research note issued on Tuesday, October 7th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($0.55) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price target on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. Cantor Fitzgerald also issued estimates for Invivyd's FY2026 earnings at ($0.65) EPS.

Several other brokerages also recently weighed in on IVVD. HC Wainwright reaffirmed a "buy" rating and set a $5.00 target price on shares of Invivyd in a research note on Wednesday, August 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Invivyd in a research report on Wednesday. Finally, D. Boral Capital increased their price objective on shares of Invivyd from $1.00 to $2.00 and gave the company a "buy" rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $5.14.

Invivyd Stock Up 0.6%

Shares of IVVD opened at $1.64 on Thursday. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $2.74. The firm's 50 day moving average price is $1.01 and its 200 day moving average price is $0.81. The company has a market cap of $197.03 million, a P/E ratio of -1.78 and a beta of 0.57.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The business had revenue of $11.79 million for the quarter, compared to analysts' expectations of $23.16 million.

Insider Activity

In other news, insider Jill Andersen sold 49,402 shares of the company's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the completion of the transaction, the insider owned 84,446 shares in the company, valued at approximately $48,134.22. This represents a 36.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 277,654 shares of company stock valued at $167,215. Corporate insiders own 25.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Invesco Ltd. boosted its holdings in shares of Invivyd by 25.5% in the 2nd quarter. Invesco Ltd. now owns 136,755 shares of the company's stock valued at $98,000 after buying an additional 27,756 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after buying an additional 28,146 shares in the last quarter. Catalyst Funds Management Pty Ltd acquired a new stake in Invivyd during the 2nd quarter worth $27,000. 683 Capital Management LLC boosted its stake in Invivyd by 2.3% during the 2nd quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock worth $2,195,000 after purchasing an additional 70,000 shares during the period. Finally, Nuveen LLC acquired a new stake in Invivyd during the 1st quarter worth $65,000. Institutional investors and hedge funds own 70.36% of the company's stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.